San Diego, CA – Daré Bioscience, a pharmaceutical company specializing in women’s health, recently held a conference call to discuss its second-quarter financial results and provide updates on its pipeline and portfolio. Led by President and CEO Sabrina Martucci Johnson and Chief Accounting Officer MarDee Haring-Layton, the call highlighted the company’s commitment to advancing innovative treatments for women’s health.
During the call, Daré Bioscience outlined its strategic approach to developing disruptive products that address unmet needs in women’s health. The company’s focus on advancing first-in-category product candidates, such as Sildenafil Cream and Ovaprene, reflects its dedication to improving women’s health outcomes.
Daré Bioscience also shared insights into its financial performance, reporting a decrease in general and administrative expenses in the second quarter of 2024. The company’s comprehensive income was driven by a royalty monetization transaction with XOMA, providing significant capital to support its late-stage investigational products.
In addition to commercializing XACIATO, the first FDA-approved product from its portfolio, Daré Bioscience highlighted its progress in advancing potential treatments for female sexual arousal disorder and hormone-free contraception. The company’s collaborations with Organon and Bayer underscore its commitment to delivering innovative solutions for women’s health.
Looking ahead, Daré Bioscience anticipates reaching key milestones in 2024, including updates on its Phase 3 studies for Sildenafil Cream and Ovaprene. With a robust pipeline of high-impact product candidates, the company is poised to make significant strides in women’s health.
As Daré Bioscience continues to focus on advancing its portfolio of innovative treatments, investors and stakeholders can expect continued progress in addressing critical health issues affecting women. The company’s relentless pursuit of groundbreaking therapies highlights its commitment to advancing women’s health and well-being.
